Oncotype DX® tests
The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to help optimize cancer treatment decisions, helping to guide treatment decisions for more than 1 million cancer patients worldwide. The Oncotype DX Breast Recurrence Score® assay is the only test that has been shown to predict the likelihood of chemotherapy benefit.
For further information, please go to oncotypeiq.com/en.
READ MORE